Preclinical Evaluation of a Novel SHIP1 Phosphatase Activator for Inhibition of PI3K Signaling in Malignant B Cells.

Elizabeth A LemmBeatriz Valle-ArgosLindsay D SmithJohanna RichterYohannes GebreselassieMatthew J CarterJana KarolovaMichael SvatonKarel Helman Nicola J Weston-BellLaura KarydisChris T WilliamsonGeorg LenzJeremy PettigrewCurtis HarwigFreda K StevensonMark S Cragg Francesco Forconi Andrew J SteeleJennifer CrossLloyd MackenziePavel KlenerGraham Packham

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2019)

Our results using AQX-435 demonstrate that SHIP1 activation may be an effective novel therapeutic strategy for treatment of B-cell neoplasms, alone or in combination with ibrutinib.

Keyphrases

nuclear factor
cell therapy
combination therapy
immune response
bone marrow